Neurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of “Hold” by Analysts

Shares of Neurogene Inc. (NASDAQ:NGNE) have been assigned an average recommendation of “Hold” from the seven brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $42.50.

NGNE has been the subject of a number of recent analyst reports. Wall Street Zen cut shares of Neurogene from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research note on Wednesday, October 8th. Finally, HC Wainwright boosted their price objective on shares of Neurogene from $65.00 to $70.00 and gave the company a “buy” rating in a report on Thursday, November 13th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets lifted its holdings in shares of Neurogene by 89.8% during the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after purchasing an additional 978 shares during the period. PNC Financial Services Group Inc. raised its position in Neurogene by 43.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock worth $61,000 after buying an additional 1,232 shares during the last quarter. Corebridge Financial Inc. raised its position in Neurogene by 13.8% during the 1st quarter. Corebridge Financial Inc. now owns 5,826 shares of the company’s stock worth $68,000 after buying an additional 705 shares during the last quarter. AlphaQuest LLC acquired a new stake in Neurogene during the 1st quarter valued at approximately $77,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Neurogene by 17.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after acquiring an additional 1,059 shares during the last quarter. 52.37% of the stock is currently owned by hedge funds and other institutional investors.

Neurogene Stock Performance

Neurogene stock opened at $20.00 on Thursday. The stock has a market cap of $309.80 million, a PE ratio of -4.87 and a beta of 1.62. The stock has a 50-day moving average of $24.73 and a two-hundred day moving average of $22.02. Neurogene has a one year low of $6.88 and a one year high of $37.27.

Neurogene (NASDAQ:NGNE) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.27. As a group, sell-side analysts predict that Neurogene will post -4.27 EPS for the current fiscal year.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.